Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FWBINASDAQ:JANNASDAQ:KRBPNASDAQ:MOTS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFWBIFirst Wave BioPharma$3.28$2.33▼$60.00$7.34M1.28212,944 shs56,500 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsMOTSMotus GI$0.00$0.00$0.00▼$0.10$2K1.024,248 shs137 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFWBIFirst Wave BioPharma0.00%0.00%0.00%0.00%0.00%JANJanOne0.00%0.00%0.00%0.00%-1.76%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-91.63%MOTSMotus GI0.00%0.00%0.00%+200.00%-99.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFWBIFirst Wave BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AMOTSMotus GI0.0874 of 5 stars0.02.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFWBIFirst Wave BioPharma 0.00N/AN/AN/AJANJanOne 0.00N/AN/AN/AKRBPKiromic BioPharma 0.00N/AN/AN/AMOTSMotus GI 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFWBIFirst Wave BioPharmaN/AN/AN/AN/A$6.54 per shareN/AJANJanOne$39.61M0.00N/AN/A($0.67) per share0.00KRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/AMOTSMotus GI$319K0.01N/AN/A$1.74 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFWBIFirst Wave BioPharma-$15.80MN/A0.00N/AN/AN/A-102.83%-22.74%N/AJANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/AKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/AMOTSMotus GI-$12.87M-$15.64N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFWBIFirst Wave BioPharmaN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFWBIFirst Wave BioPharma0.401.211.58JANJanOneN/A0.150.15KRBPKiromic BioPharmaN/A0.160.22MOTSMotus GIN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFWBIFirst Wave BioPharma12.30%JANJanOne6.27%KRBPKiromic BioPharma10.91%MOTSMotus GI20.06%Insider OwnershipCompanyInsider OwnershipFWBIFirst Wave BioPharma0.49%JANJanOne3.00%KRBPKiromic BioPharma20.59%MOTSMotus GI0.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFWBIFirst Wave BioPharma92.48 million2.46 millionNot OptionableJANJanOne1708.98 million8.71 millionNot OptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionableMOTSMotus GI305.77 million5.75 millionNot OptionableJAN, KRBP, FWBI, and MOTS HeadlinesRecent News About These CompaniesMotus GI Hldgs (OTC:MOTS) Stock, Insider Trading ActivityDecember 13, 2024 | benzinga.comMotus GI Hldgs (OTC:MOTS) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comMotus GI Hldgs (OTC:MOTS) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comMotus GI annonce la démission de son conseil d'administration et l'arrêt de ses activitésJuly 31, 2024 | fr.investing.comDividende Motus GI Holdings, Inc.July 25, 2024 | zonebourse.comDividendes sectoriels Motus GI Holdings, Inc.July 25, 2024 | zonebourse.comMOTS Stock Earnings: Motus GI Hldgs Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comMotus GI Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | finance.yahoo.comMotus GI Holdings IncApril 16, 2024 | morningstar.comWhy Is Motus GI (MOTS) Stock Down 37% Today?April 12, 2024 | msn.comWhy Is Motus GI (MOTS) Stock Down 37% Today?April 12, 2024 | investorplace.comMotus GI Holdings files to sell 4.4M common shares for holdersMarch 23, 2024 | msn.comMotus GI Holdings, Inc.: Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 19, 2024 | finanznachrichten.deMOTS Stock Earnings: Motus GI Hldgs Misses EPS, Misses Revenue for Q4 2023March 18, 2024 | investorplace.comLe BPA de Motus GI Holdings a dépassé les attentes de 1,30$, le CA en dessous des prévisionsMarch 18, 2024 | fr.investing.comMotus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 18, 2024 | globenewswire.comMotus GI Holdings, Inc. (MOTS)February 29, 2024 | finance.yahoo.comEndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive OfficerFebruary 29, 2024 | businesswire.comMotus GI secures new patent for endoscopic proceduresFebruary 23, 2024 | investing.comMotus GI Holdings Inc.February 23, 2024 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesBy Chris Markoch | June 21, 2025View Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesJAN, KRBP, FWBI, and MOTS Company DescriptionsFirst Wave BioPharma NASDAQ:FWBIFirst Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Kiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Motus GI NASDAQ:MOTS$0.0003 0.00 (0.00%) As of 06/20/2025 10:25 AM EasternMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
